Drug intelligence / Profile preview

sotetinib

Development stage: Phase 3
Lead developer: Shouyao Holdings
Modality: Small Molecules
Administration: Oral

Overview

Sotetinib (SY-5007) is a selective, small-molecule inhibitor of the RET (rearranged during transfection) tyrosine kinase, developed by Shouyao Holdings. It is designed to treat advanced solid tumors harboring RET alterations, such as RET fusions or mutations. These alterations are common drivers in non-small cell lung cancer (NSCLC) and medullary thyroid cancer (MTC). Sotetinib works by binding to the RET kinase domain, thereby blocking downstream signaling pathways that promote tumor cell growth and survival. Clinical data indicates significant anti-tumor activity in RET-altered patients, with a manageable safety profile. It is currently in Phase III development for RET fusion-positive NSCLC in China.

Other names: SY-5007SY5007SY 5007

Targets

RET (Rearranged during transfection receptor tyrosine kinase)

Beyond the preview

Go deeper on sotetinib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on sotetinib.

Explore the full profile